mavacamten

mavacamten U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) PRINCETON, N.J.–(BUSINESS WIRE)– March 19,

Read more